Edwards Lifesciences (NYSE:EW) SVP Sells $49,536.64 in Stock

Edwards Lifesciences Corporation (NYSE:EW) SVP Andrew Dahl sold 544 shares of the stock in a transaction that occurred on Monday, August 31st. The stock was sold at an average price of $91.06, for a total value of $49,536.64. Following the sale, the senior vice president owned 14,868 shares in the company, valued at approximately $1,353,880.08. This trade represents a 3.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Edwards Lifesciences Trading Up 0.1%

EW opened at $90.80 on Thursday. Edwards Lifesciences Corporation has a 1-year low of $72.30 and a 1-year high of $96.29. The stock has a market capitalization of $52.28 billion, a PE ratio of 52.18, a PEG ratio of 2.38 and a beta of 0.85. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The firm has a 50-day moving average price of $89.74 and a two-hundred day moving average price of $85.36.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion during the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter in the previous year, the company posted $0.67 earnings per share. The firm’s quarterly revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities analysts anticipate that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research reports. JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. Wall Street Zen cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. BTIG Research increased their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Tuesday, June 30th. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Finally, UBS Group started coverage on Edwards Lifesciences in a research note on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. Seventeen research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $100.27.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of the stock. Hanson & Doremus Investment Management acquired a new position in shares of Edwards Lifesciences during the 1st quarter worth approximately $25,000. JPL Wealth Management LLC bought a new stake in shares of Edwards Lifesciences in the third quarter valued at approximately $25,000. MV Capital Management Inc. acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences during the 1st quarter worth $26,000. Finally, Pin Oak Investment Advisors Inc. bought a new position in Edwards Lifesciences during the 2nd quarter worth $26,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.